Summary
The pharmacokinetics of low-dose aspirin and the resulting salicylic acid were studied in 6 healthy volunteers. Each received a single 50-mg dose of (1) oral modified release capsules, (2) oral solution and (3) intravenous solution. The volunteers also received 50 mg modified release capsules daily for 6 days to determine the effect on collagen, ADP and arachidonate induced platelet aggregation and thromboxane production, and to compare the pharmacokinetics after repeated dosing with the parameters obtained after the single dose.
The formulation and route of administration profoundly influenced several pharmacokinetic parameters for aspirin: the maximum concentration (Cmax, ng·ml−1) was 221 and 191 after modified release for single and chronic dosing respectively, 1323 after the oral solution and 6000 after intravenous injection; the time to achieve this maximum concentration (tmax, h) was 3.42 and 3.02 after modified release for single and chronic dosing respectively, and 0.29 after the oral solution; the area under the plasma drug concentration versus time curve (AUC, µg·h·ml−1) was 0.38 and 0.27 after modified release single and chronic dosing respectively, 0.68 after the oral solution and 1.57 after intravenous injection.
The elimination of aspirin after the two solutions was at least biphasic. The terminal phase rate constant ranged from 1.52 h−1 after intravenous injection to 1.88 h−1 after the oral modified release form. The absorption of the oral forms of aspirin was complete as reflected by the total recovery of the doses as salicylic acid in urine. The pharmacokinetic parameters for salicylic acid showed similar tmax and Cmax for the oral solution and intravenous injection but, as for aspirin, Cmax was least and tmax greatest when the modified release form was used.
After 7 days of modified release aspirin platelet aggregation and thromboxane formation in response to collagen and arachidonate were markedly inhibited. There was no inhibition of ADP-induced aggregation, but thromboxane production in response to ADP was abolished.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ali M, McDonald JWD, Thiessen JJ, Coates PE (1980) Plasma acetyl-salicylate and salicylate and platelet cyclooxygenase activity following plain and enteric-coated aspirin. Stroke 11: 9–13
Antiplatelet Trialists' Collaboration (1988) Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J 296: 320–331
Bochner F, Lloyd J (1986) Is there an optimal dose and formulation of aspirin to prevent arterial thromboembolism in man? Clin Sci 71: 625–631
Boxenbaum HG, Riegelman S, Elashoff RM (1974) Statistical estimations in pharmacokinetics. J Pharmacokinet Biopharm 2: 123–148
Brandon RA, Eadie MJ, Smith MT (1985) A sensitive liquid chromatographic assay for plasma aspirin and salicylate concentrations after low doses of aspirin. Ther Drug Monit 7: 216–221
Burch JW, Baenziger NL, Stanford N, Majerus PW (1978) Sensitivity of fatty acid cyclooxygenase from human aorta to acetylation by aspirin. Proc Nat Acad Sci USA 75: 5181–5184
Cham BE, Ross-Lee L, Bochner F, Imhoff DM (1980) Measurement and pharmacokinetics of acetylsalicylic acid by a novel high performance liquid chromatographic assay. Ther Drug Monit 2: 365–372
Daniel WW (1983) Biostatistics: A foundation for analysis in the health sciences (3rd edn). Wiley & Sons, New York
Emmett JAG, Brandon RA, Ulcoq A, Eadie MJ, Bunce IH (1987) Plasma aspirin concentrations to inhibit platelet aggregation in diabetes. Clin Exp Pharmacol Physiol 10 [Suppl]: 78–79
Fields WS, Lemak NA, Frankowski RF, Hardy RJ (1977) Controlled trial of aspirin in cerebral ischemia. Stroke 8: 301–316
Fitzpatrick FA (1982) A radioimmunoassay for thromboxane B2 In: Lands WEM, Smith Wh (eds) Methods in enzymology. Academic Press, London, p 286
Gallus AS (1985) Aspirin and the other platelet aggregating inhibiting drugs. Med J Aust 142: 141–147
Gibaldi M, Perrier D (1982) Pharmacokinetics (2nd edn). Marcel Dekker, New York
Hanley SP, Cockbill SR, Bevan J, Heptinstall S (1981) Differential inhibition by low-dose aspirin of human venous prostacyclin synthesis and thromboxane synthesis. Lancet 1: 969–971
Herd CM, Rodgers SE, Lloyd JV, Bochner F, Duncan EM, Tunbridge LJ (1987) A dose-ranging study of the antiplatelet effect of enteric coated aspirin in man. Aust NZ J Med 17: 195–200
Ho FC, Triggs EJ, Bourne DWA, Heazlewood VJ (1985) The effects of age and sex on the disposition of acetylsalicylic acid and its metabolites. Br J Clin Pharmacol 19: 675–684
Levy G, Tsuchiya T, Amsel LP (1972) Limited capacity for salicyl phenolic glucuronide formation and its effect on the kinetics of salicylate elimination in man. Clin Pharmacol Ther 13: 258–268
Lewis DH, Davis JW, Archibald DG, Steinke WE, Smitheram TC, Doherty JE III, Schnaper HW, LeWinter MM, Linares E, Pouget JM, Sabharwal SC, Chesler E, DeMots H (1983) Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. N Engl J Med 309: 396–403
Menguy R, Desbaillets L, Masters YF, Okabe S (1972) Evidence for a sex-linked difference in aspirin metabolism. Nature 239: 102–103
Pedersen AK, FitzGerald GA (1984) Dose-related kinetics of aspirin. N Engl J Med 311: 1206–1211
Pedersen AK, FitzGerald GA (1985) Preparation and analysis of deuterium labelled aspirin: Application to pharmacokinetic studies. J Pharm Sci 74: 188–192
Preston FE, Whipps S, Jackson CA, French AJ, Wyld PJ (1981) Inhibition of prostacyclin and platelet thromboxane A2 after low-dose aspirin. N Engl J Med 304: 76–79
Riegelman S, Collier P (1980) The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time. J Pharmacokin Biopharm 8: 509–533
Roberts MS, McLeod LJ, Cossum PA, Vial JH (1984) Inhibition of platelet function by a controlled release acetylsalicylic acid formulation — single and chronic dosing studies. Eur J Clin Pharmacol 27: 67–74
Ross-Lee LM, Elms MJ, Cham BE, Bochner F, Bunce IH, Eadie MJ (1982) Plasma levels of aspirin following effervescent and enteric coated tablets, and their effect on platelet function. Eur J Clin Pharmacol 23: 545–551
Rowland M, Riegelman S (1968) Pharmacokinetics of acetylsalicylic acid and salicylic acid after intravenous administration in man. J Pharm Sci 57: 1313–1319
Rowland M, Riegelman S, Harris PA, Sholkoff SD (1972) Absorption kinetics of aspirin in man following oral administration of an aqueous solution. J Pharm Sci 61: 379–385
Rowland M, Riegelman S, Harris PA, Sholkoff SD, Eyring EJ (1967) Kinetics of acetylsalicylic acid disposition in man. Nature 215: 413–414
Rumble RH, Roberts MS, Wanwimolruk S (1981) Determination of aspirin and its major metabolites in plasma by high-performance liquid chromatography without solvent extraction. J Chromatogr 225: 252–260
Siebert DJ, Bochner F, Imhoff DM, Watts S, Lloyd JV, Field J, Gabb BW (1983) Aspirin kinetics and platelet aggregation in man. Clin Pharmacol Ther 33: 367–374
Siebert DM, Bochner F (1987) Determination of plasma aspirin and salicylic acid concentrations after low aspirin doses by high performance liquid chromatography with post column hydrolysis and fluorescence detection. J Chromatogr 420: 425–431
Sils D, Rodgers SE, Lloyd JV, Wilson KM, Siebert DM, Bochner F (1988) Inhibition of platelet aggregation and thromboxane production by low concentrations of aspirin in vitro. Clin Sci 74: 491–497
Yamaoka K, Nakagawa T, Uno T (1978) Statistical moments in pharmacokinetics. J Pharmacokinet Biopharm 6: 547–557
Zucker MB, Peterson J (1970) Effect of acetylsalicylic acid, other nonsteroidal anti-inflammatory agents, and dipyridamole on human blood platelets. J Lab Clin Med 76: 66–75
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bochner, F., Williams, D.B., Morris, P.M.A. et al. Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function. Eur J Clin Pharmacol 35, 287–294 (1988). https://doi.org/10.1007/BF00558267
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00558267